International Journal of Women''s Dermatology最新文献

{"title":"COVID-19 vaccination among patients with cicatricial alopecia: patient concerns, experiences, and treatment modifications.","authors":"Kelly E Flanagan, James T Pathoulas, Maryanne M Senna, Chloe J Walker, Isabel Pupo Wiss, Maya Collins, Shaheir Ali, Rita Wanser, Jean Pickford, Wilma Bergfeld","doi":"10.1097/JW9.0000000000000036","DOIUrl":"https://doi.org/10.1097/JW9.0000000000000036","url":null,"abstract":"","PeriodicalId":53478,"journal":{"name":"International Journal of Women''s Dermatology","volume":"9 1","pages":"e036"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/51/19/jw9-9-e036.PMC9973349.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10824275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analyzing trends in treatment of acne vulgaris in pregnancy: a retrospective study.","authors":"Swati P Garg, Saira Alvi, Roopal V Kundu","doi":"10.1097/JW9.0000000000000076","DOIUrl":"https://doi.org/10.1097/JW9.0000000000000076","url":null,"abstract":"Acne vulgaris is an inflammatory disease of the skin common in pregnancy.1 Many first-line acne treatments are teratogenic, complicating management of this condition (Table 1).2 Although recommendations from the American Board of Family Medicine (ABFM) exist for treatment of acne in pregnancy,3 no studies have analyzed real-life data of acne management in pregnant patients. A retrospective study utilizing patient data from the Northwestern Medicine Enterprise Data Warehouse was approved by the Northwestern University Institutional Review Board (STU00037913). Data from over 40 clinic locations and 100 providers across the Chicago metropolitan area resulted in 4,050 analyzed patient encounters with a diagnosis of acne vulgaris. One hundred fifteen of these visits occurred in pregnancy-related encounters. Within our 115 patients, 57.4% (66) of patients were trying to get pregnant within the next year, 32.2% (37) were pregnant, and 10.4% (12) were breastfeeding (Table 2). Patients in this cohort were exclusively prescribed pregnancy category B and C medications.2 Azelaic acid 15% gel and clindamycin 1% gel, solution, or lotion were the most commonly prescribed treatments with 83.3% (55/66) and 69.7% (46/66) of patients trying to get pregnant and 75.7% (28/37) and 56.8% (21/37) of pregnant patients prescribed these medications, respectively. Only 13.5% (5/37) of currently pregnant patients were prescribed category C prescriptions, suggesting safe treatment of acne in pregnancy. In nonpregnancy-related encounters, prescription rates of azelaic acid (4.5%, 178/3,935) and clindamycin (54.0%, 2,124/3,935) were lower and recommendation rates of other pregnancy C medications including retinoids (59.8%, 2,355/3,935), spironolactone (10.2%, 401/3,935), and dapsone (9.1%, 358/3,935) were higher compared to pregnancy-related encounters. These findings suggest substantial adjustment of acne treatment regimens for safety in pregnancy and peri-pregnancy and recognition of the teratogenic effects of acne medications by providers. ABFM guidelines recommend avoidance of antibiotic monotherapy and encourage use of benzoyl peroxide as first-line treatment of acne in pregnancy to avoid antibiotic resistance.3,4 Of 37 pregnant patients, 6 (16.2%) were prescribed antibiotic monotherapy which was higher than the rate of 6.9% (270/3,935) in the nonpregnant population. Benzoyl peroxide 2.5–10% in the form of a face wash, cream, or gel was recommended at lower rates in the pregnant group (13.5%, 5/37) compared to those not pregnant (46.4%, 1,825/3,935). The higher rates of antibiotic monotherapy and lower rates of benzoyl peroxide prescribed in pregnant patients may reflect the limitations for ideal acne treatment and highlight a potential area for improvement. One limitation of this study is the relatively small sample size. Although prescription trends and generalizations can be inferred from the data, the sample size is not large enough to determine statistical significanc","PeriodicalId":53478,"journal":{"name":"International Journal of Women''s Dermatology","volume":"9 1","pages":"e076"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9a/1b/jw9-9-e076.PMC9997801.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9453743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Podiatric assessment in children and adults with epidermolysis bullosa: are foot and ankle patient-reported outcome measures (PROMs) able to measure the severity of podiatric involvement among EB patients?","authors":"Joy Lynn Wong,&nbsp;Mohammed Tariq Khan,&nbsp;Timothy L Cowan,&nbsp;Dedée F Murrell","doi":"10.1097/JW9.0000000000000046","DOIUrl":"https://doi.org/10.1097/JW9.0000000000000046","url":null,"abstract":"<p><p>Epidermolysis bullosa (EB) represents a group of rare genetic skin fragility disorders characterized by (muco) cutaneous blistering upon minimal mechanical trauma. Ninety percent of EB patients experience podiatric symptoms which may affect physical functioning and emotional well-being. To date, an EB-specific podiatric assessment has not been outlined to guide clinicians in the assessment of EB podiatric involvement. This review describes the podiatric involvement of patients with EB and assesses the relevance of validated foot and ankle patient-reported outcome measures (PROMs) in measuring podiatric severity among EB patients. A literature review was conducted to identify systematic reviews and clinical studies investigating foot health and podiatric manifestations using validated foot health PROMs across foot and ankle conditions. Limited studies have documented the significance of podiatric involvement among EB patients. Existing EB-specific PROMs are not region-specific for assessing podiatric involvement. Among the foot and ankle PROMs, the Foot Health Status Questionnaire, Foot Function Index, and Manchester Oxford Foot Questionnaire were identified as potentially appropriate for assessing podiatric severity among EB patients, each with its strengths and limitations in assessment. However, they have not been widely validated for assessing dermatology-related diseases. An evaluation of the relevance of each identified PROM to EB podiatric assessment would enable future development of an appropriate EB-specific podiatric assessment tool that would guide management.</p>","PeriodicalId":53478,"journal":{"name":"International Journal of Women''s Dermatology","volume":"9 1","pages":"e046"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9851710/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9178572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dermatologic toxicities of chemotherapy: an educational intervention for skin of color women with breast cancer.","authors":"Maham Ahmad,&nbsp;Sabrina Saeed,&nbsp;Brianna Olamiju,&nbsp;Andrea Silber,&nbsp;Jonathan Leventhal","doi":"10.1097/JW9.0000000000000073","DOIUrl":"https://doi.org/10.1097/JW9.0000000000000073","url":null,"abstract":"<p><p>Minority patients are more likely to require dose adjustments for chemotherapy, with cultural barriers and access to medical care cited as contributory factors.</p><p><strong>Objective: </strong>We sought to pilot an educational intervention, in the form of a pamphlet, to evaluate the effectiveness of this tool in teaching skin of color (SoC) patients about potential dermatologic toxicities of chemotherapy that are relevant to their skin type.</p><p><strong>Methods: </strong>At a chemotherapy infusion center, SoC patients (<i>n</i> = 26) who were receiving chemotherapy for breast cancer voluntarily consented to read an educational pamphlet and complete a series of survey questions before and after this educational intervention.</p><p><strong>Results: </strong>Most participants identified as female (96%), African American/Black (81%), and non-Hispanic (85%); all respondents had obtained at least a high school degree. Survey responses revealed a significant increase in knowledge about the potential dermatologic effects of cancer treatment after this intervention. Notably, 100% of participants either agreed or strongly agreed that they would like to see other doctors use this educational tool as a form of patient education, that they would recommend this pamphlet to other patients who are starting cancer treatment, and that the pamphlet was easy to understand.</p><p><strong>Limitations: </strong>Limitations of this study include small sample size and single-institution recruitment, which may limit generalizability. Furthermore, this study only included patients who are proficient in English.</p><p><strong>Conclusion: </strong>This study pilots an effective educational tool that addresses dermatologic toxicities of chemotherapy that are relevant to SoC patients. Further multi-institutional studies with larger sample sizes and translation to other languages can overcome the limitations of this pilot study.</p>","PeriodicalId":53478,"journal":{"name":"International Journal of Women''s Dermatology","volume":"9 1","pages":"e073"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886509/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9170951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deodorant/antiperspirant use and hair removal practices for hidradenitis suppurativa: recommendations from a single-center survey.","authors":"Brett Cutler,&nbsp;Erika Hagstrom,&nbsp;Teri M Greiling","doi":"10.1097/JW9.0000000000000028","DOIUrl":"https://doi.org/10.1097/JW9.0000000000000028","url":null,"abstract":"Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder that frequently affects the axillae. Axillae are also tar-geted for societal hygiene practices: namely, the use of deodor- ants and antiperspirants and techniques for hair removal. HS is associated with an increased risk of hyperhidrosis and female hirsutism due to polycystic ovarian disease, further increasing the impact of these practices on quality of life. 1,2 Patients with HS are often unsure how to appropriately target physiologi- cal body odor and hair removal without worsening their HS. A 1982 case-control study concluded simply that deodorant, shaving, and chemical depilatories are not causative of HS, 3 but little guidance beyond this is available for patients or their providers.","PeriodicalId":53478,"journal":{"name":"International Journal of Women''s Dermatology","volume":"9 1","pages":"e028"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a9/09/jw9-9-e028.PMC9833445.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9178571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of lichen sclerosus and morphea with immune checkpoint therapy: a systematic review.","authors":"Leah Shin,&nbsp;Janellen Smith,&nbsp;Jessica Shiu,&nbsp;Christina N Kraus,&nbsp;Ashley N Elsensohn","doi":"10.1097/JW9.0000000000000070","DOIUrl":"https://doi.org/10.1097/JW9.0000000000000070","url":null,"abstract":"The use of immune checkpoint inhibitors (ICIs) has been asso- ciated with various cutaneous immune-related adverse events (irAEs), including eczematous, psoriasiform, lichenoid, and bul- lous dermatoses. 1,2 Here, we evaluated reports of lichen sclerosus (LS) and morphea associated with ICIs. A literature search was conducted October 7, 2022 of PubMed, Cochrane, Embase, CINAHL, and Web of Science. Search terms: “lichen sclerosus,” “scleroderma, localized,” “mor-phea,” “immune checkpoint inhibitor,” “immunotherapy,” “ipili- mumab,” “nivolumab,” “pembrolizumab,” “atezolizumab,” avelumab,” “durvalumab,” “cemiplimab,” “dostarlimab,” and “relatlimab,” yielding 318 studies. Titles, abstracts, and full-text manuscripts were screened for relevance. Twenty-three studies were included","PeriodicalId":53478,"journal":{"name":"International Journal of Women''s Dermatology","volume":"9 1","pages":"e070"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c6/e4/jw9-9-e070.PMC9851696.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9191205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A rare case of viral-associated trichodysplasia spinulosa in a patient with chronic lymphocytic leukemia.","authors":"Rachel Choi,&nbsp;Shaman Bhullar,&nbsp;Jennifer McNiff,&nbsp;Justin Persico,&nbsp;Jonathan Leventhal","doi":"10.1097/JW9.0000000000000069","DOIUrl":"https://doi.org/10.1097/JW9.0000000000000069","url":null,"abstract":"Viral-associated trichodysplasia spinulosa (VATS) is a cuta- neous eruption of folliculo-centric shiny papules and alo-pecia that most commonly occurs in transplant recipient patients. 1 Here, we present an extremely rare case of VATS in a female patient with chronic lymphocytic leukemia (CLL). An informed consent was obtained from the patient for this report.A 63-year-old female presented with a 2-month history of multiple reddish-pinkish papules on her face in the setting of long-standing CLL. Physical examination also showed leonine facies, superciliary madarosis","PeriodicalId":53478,"journal":{"name":"International Journal of Women''s Dermatology","volume":"9 1","pages":"e069"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949812/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9170983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vulvar allergic contact dermatitis to multiple acrylates: a case report.","authors":"Núria Riera-Martí,&nbsp;Vicente Expósito-Serrano,&nbsp;Maria Sin,&nbsp;Marta Gamissans,&nbsp;Cristina López-Llunell,&nbsp;Miquel Ribera","doi":"10.1097/JW9.0000000000000077","DOIUrl":"https://doi.org/10.1097/JW9.0000000000000077","url":null,"abstract":"","PeriodicalId":53478,"journal":{"name":"International Journal of Women''s Dermatology","volume":"9 1","pages":"e077"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d3/46/jw9-9-e077.PMC9997830.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9453741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patterns of insurance coverage for wigs in patients with alopecia areata: a cross-sectional survey.","authors":"Ogechi Ezemma,&nbsp;Shivali Devjani,&nbsp;Aidan Lee,&nbsp;Kristen J Kelley,&nbsp;Lisa Anderson,&nbsp;Nicole Friedland,&nbsp;Maryanne Senna","doi":"10.1097/JW9.0000000000000075","DOIUrl":"https://doi.org/10.1097/JW9.0000000000000075","url":null,"abstract":"","PeriodicalId":53478,"journal":{"name":"International Journal of Women''s Dermatology","volume":"9 1","pages":"e075"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/90/24/jw9-9-e075.PMC9916017.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10697999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A cross-sectional study of contact allergens in feminine hygiene wipes: a possible cause of vulvar contact dermatitis.","authors":"Jazmin Newton,&nbsp;Sophie Richardson,&nbsp;Annika M van Oosbre,&nbsp;Jiade Yu,&nbsp;Channi Silence","doi":"10.1097/JW9.0000000000000060","DOIUrl":"https://doi.org/10.1097/JW9.0000000000000060","url":null,"abstract":"<p><p>Feminine hygiene wipes marketed toward women for maintaining freshness and cleanliness of the vulva and perineum are abundant both in-store and online. Many of these products boast being \"fragrance free,\" \"gentle,\" and \"for sensitive skin,\" which is attractive to consumers. However, these claims do not necessarily mean they are free of potential allergens.</p><p><strong>Objective: </strong>The present study aims to investigate the presence and prevalence of potential allergens in the most used feminine hygiene wipes.</p><p><strong>Methods: </strong>An internet-based search was performed to identify best-selling name brand and generic feminine hygiene wipes. Each unique wipe was analyzed and compared to the North American Contact Dermatitis Group 80 allergens.</p><p><strong>Results: </strong>We found contact allergens are frequently present in feminine hygiene wipes, most commonly fragrances, other scented botanicals in the form of essences, oils, and fruit juices, and vitamin E (tocopherol). All wipes analyzed in this study contained potential allergens.</p><p><strong>Limitations: </strong>The inability to eliminate commercial names from analysis could have introduced bias.</p><p><strong>Conclusions: </strong>Vaginal and vulvar epithelia are highly susceptible to contact allergens, often found in products marketed for feminine hygiene and cleanliness. Providers should caution patients against trusting product labeling claims to avoid incidental contact allergy and encourage simply cleansing the vulva with water.</p>","PeriodicalId":53478,"journal":{"name":"International Journal of Women''s Dermatology","volume":"8 4","pages":"e060"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9699505/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10463330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}